Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
By R. Kyle, E. Remstein, Terry M. Therneau, A. Dispenzieri, Paul J. Kurtin, J. Hodnefield, D. Larson, M. Plevak, D. Jelinek, R. Fonseca and 2 more. New England Journal of Medicine, 2007
858 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/261c62645a4a37b7c950237ad39b7aa9019675d3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
In Molecular Biology
Citations in the corpus
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009, methodology): “The extent of abnormality of rFLC was independent of SMM risk categories defined by the number of bone marrow plasma cells (BMPC) and size of serum M proteins.(23) A risk model was constructed, incorporating the best breakpoint of rFLC, BMPC ≥ 10%, and serum M protein ≥3 g/dL.”
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010, background): “plasma cells, a risk-stratification model was developed (20).”
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009, background): “Although SMM has a much higher risk of progression to symptomatic myeloma (10% per year in the first 5 years), many of these patients can be observed for years before any active therapy is required.(26) Given the lack of any demonstrated benefit for initiating therapy for this early disease stage,(2”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.(18) Patients with the highest risk of”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically.(20) SMM progresses to multiple myeloma at a rate of approximately 10% per year over the first 5 years following diagnosis, 3% per year ov”